1,060,000 Shares of Xeris Biopharma Holdings, Inc. $XERS Bought by Vilga Financial Planning LLC

Key Points

• Vilga Financial Planning LLC acquired 1.06 million Xeris Biopharma shares worth approximately $10.1 million, making XERS its third-largest portfolio holding and representing about 0.58% of the company.
• Institutional interest increased, with several firms initiating or expanding positions; institutional investors and hedge funds now own approximately 42.75% of Xeris.
• XERS was trading near $10.19, while analysts held a mixed outlook: the consensus rating was “Hold” with an average price target of $13.20, despite recent target increases from Barclays and Leerink Partners.

Vilga Financial Planning LLC purchased a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,060,000 shares of the company's stock, valued at approximately $10,134,000. Xeris Biopharma accounts for approximately 6.1% of Vilga Financial Planning LLC's portfolio, making the stock its 3rd largest holding. Vilga Financial Planning LLC owned approximately 0.58% of Xeris Biopharma at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of XERS. Walleye Capital LLC acquired a new position in Xeris Biopharma during the second quarter worth $4,841,000. Legal & General Group Plc acquired a new stake in shares of Xeris Biopharma in the 2nd quarter valued at $15,941,000. Canada Pension Plan Investment Board bought a new stake in shares of Xeris Biopharma in the 2nd quarter worth about $1,736,000. Janus Henderson Group PLC grew its holdings in shares of Xeris Biopharma by 322.8% in the 1st quarter. Janus Henderson Group PLC now owns 295,489 shares of the company's stock worth $1,713,000 after purchasing an additional 225,602 shares during the last quarter. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of Xeris Biopharma during the 1st quarter worth about $1,456,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Trading Up 0.8%

NASDAQ XERS opened at $10.19 on Friday. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $11.33. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The firm has a market cap of $1.86 billion, a P/E ratio of -92.64 and a beta of 0.53. The stock's 50-day moving average is $8.61 and its 200-day moving average is $7.45.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on XERS shares. Weiss Ratings cut shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Leerink Partners boosted their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a report on Thursday, September 10th. Wall Street Zen upgraded Xeris Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Finally, Barclays raised their target price on Xeris Biopharma from $12.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $13.20.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $9.41, for a total value of $47,050.00. Following the sale, the insider owned 1,351,053 shares of the company's stock, valued at $12,713,408.73. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the business's stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.41, for a total value of $156,827.06. Following the completion of the sale, the insider owned 1,111,130 shares in the company, valued at approximately $10,455,733.30. This trade represents a 1.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 134,998 shares of company stock worth $1,202,666. Corporate insiders own 4.35% of the company's stock.

Xeris Biopharma Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing's syndrome.

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.